Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report)'s share price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $12.70 and traded as high as $13.19. Benitec Biopharma shares last traded at $12.88, with a volume of 191,439 shares changing hands.
Wall Street Analysts Forecast Growth
BNTC has been the topic of a number of recent analyst reports. Evercore started coverage on shares of Benitec Biopharma in a research report on Tuesday, May 12th. They set an "outperform" rating and a $25.00 price target on the stock. Wedbush assumed coverage on shares of Benitec Biopharma in a report on Tuesday, July 28th. They issued an "outperform" rating and a $16.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Benitec Biopharma in a research note on Friday, July 17th. Wall Street Zen raised Benitec Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Guggenheim downgraded Benitec Biopharma from a "buy" rating to a "neutral" rating in a research report on Wednesday, June 10th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $24.80.
View Our Latest Report on BNTC
Benitec Biopharma Trading Up 4.6%
The company has a market cap of $442.43 million, a price-to-earnings ratio of -11.30 and a beta of 0.27. The business has a 50-day moving average price of $12.70 and a 200 day moving average price of $11.94.
Institutional Trading of Benitec Biopharma
Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 904 shares in the last quarter. GAMMA Investing LLC lifted its position in Benitec Biopharma by 18.7% in the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company's stock worth $107,000 after buying an additional 1,256 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in Benitec Biopharma by 0.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 262,205 shares of the biotechnology company's stock worth $3,532,000 after buying an additional 1,786 shares in the last quarter. Barclays PLC boosted its stake in shares of Benitec Biopharma by 9.1% during the 4th quarter. Barclays PLC now owns 23,211 shares of the biotechnology company's stock valued at $313,000 after buying an additional 1,928 shares during the period. Finally, Truvestments Capital LLC boosted its stake in shares of Benitec Biopharma by 156.5% during the 4th quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company's stock valued at $52,000 after buying an additional 2,339 shares during the period. Hedge funds and other institutional investors own 52.19% of the company's stock.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Ltd NASDAQ: BNTC is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
